Quantity | = | Concentration | x | Volume | x | Molecular Weight |
---|---|---|---|---|---|---|
= | x | x |
1) Click the Molarity Calculation Cart® button.
2) Specify the Concentration and Volume of your desired Molarity.
3) Click Calculate.
4) Your desired Quantity will be calculated and will be put under Quantity: (only for mg)
5) Click Add to Cart and then Proceed to checkout to complete the order. You will receive the quantity as you ordered as solvent-free form.
Alert: If you want to make a solution with a solvent (such DMSO), please add instructions in the notes section (such as 10 nM/1 mL in DMSO) and we will pack and deliver the product as a solution (such as 10 nM solution in 1 mL DMSO). If the product cannot be dissolved in DMSO or you would like to specify your own preferred solvent, please add detailed instructions in the notes section. All solutions must be shipped with an ice bag, costing an additional fee of $20 for S&H.
AOB87674
CAS: 1365267-27-1
Chemical Name: Ensartinib; (R)-6-Amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-(4-methylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide
Warning: Last items in stock!
Availability date:
Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
---|---|---|---|
1 | 100 | $11.25 | Total: $1,125.00 |
1 | 50 | $13.00 | Total: $650.00 |
1 | 25 | $15.25 | Total: $381.25 |
1 | 10 | $18.00 | Total: $180.00 |
1 | 5 | $21.25 | Total: $106.25 |
Molecular Formula | C25H25Cl2FN6O3 |
Molecular Weight | 547.41 |
CAS Numbers | 1370651-20-9 |
Storage Condition | 0°C (short term), -20°C (long term), desiccated |
Solubility | DMSO |
Purity | 98% by HPLC |
Synonym | X-376; X 376; X376; Ensartinib-analog; X 396-analog; X396-analog; X-396-analog; |
IUPAC/Chemical Name | 6-Amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-N-[4-[(4-methyl-1-piperazinyl)carbonyl]phenyl]-3-pyridazinecarboxamide |
InChl Key | ONPGOSVDVDPBCY-CQSZACIVSA-N |
InChl Code | InChI=1S/C25H25Cl2FN6O3/c1-14(21-17(26)7-8-18(28)22(21)27)37-20-13-19(31-32-23(20)29)24(35)30-16-5-3-15(4-6-16)25(36)34-11-9-33(2)10-12-34/h3-8,13-14H,9-12H2,1-2H3,(H2,29,32)(H,30,35)/t14-/m1/s1 |
SMILES Code | O=C(C1=NN=C(N)C(O[C@@H](C2=C(Cl)C=CC(F)=C2Cl)C)=C1)NC3=CC=C(C(N4CCN(C)CC4)=O)C=C3 |
References | 1) Sullivan I, Planchard D. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol. 2016 Jan;8(1):32-47. doi: 10.1177/1758834015617355. Review. PubMed PMID: 26753004; PubMed Central PMCID: PMC4699265. 2) Qiu W, Yuchi M, Ding M, Tessier D, Fenster A. Needle segmentation using 3D Hough transform in 3D TRUS guided prostate transperineal therapy. Med Phys. 2013 Apr;40(4):042902. doi: 10.1118/1.4795337. PubMed PMID: 23556924. |
Novel potent and highly specific ALK tyrosine kinase inhibitor (TKI)